NO20043663L - Bicykliske aminosyrer som farmasoytiske midler - Google Patents

Bicykliske aminosyrer som farmasoytiske midler

Info

Publication number
NO20043663L
NO20043663L NO20043663A NO20043663A NO20043663L NO 20043663 L NO20043663 L NO 20043663L NO 20043663 A NO20043663 A NO 20043663A NO 20043663 A NO20043663 A NO 20043663A NO 20043663 L NO20043663 L NO 20043663L
Authority
NO
Norway
Prior art keywords
amino acids
pharmaceutical agents
bicyclic amino
bicyclic
pharmaceutical
Prior art date
Application number
NO20043663A
Other languages
English (en)
Inventor
Justin Stephen Bryans
David Clive Blakemore
Simon Osborne
Jean-Marie Receveur
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20043663L publication Critical patent/NO20043663L/no
Application filed by Warner Lambert Co filed Critical Warner Lambert Co

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/18All rings being cycloaliphatic the ring system containing six carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/20All rings being cycloaliphatic the ring system containing seven carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/22All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/24All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14All rings being cycloaliphatic
    • C07C2602/26All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
NO20043663A 1999-10-20 2004-09-01 Bicykliske aminosyrer som farmasoytiske midler NO20043663L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20
PCT/US2000/028687 WO2001028978A1 (en) 1999-10-20 2000-10-17 Bicyclic amino acids as pharmaceutical agents

Publications (1)

Publication Number Publication Date
NO20043663L true NO20043663L (no) 2002-04-16

Family

ID=22578159

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20021780A NO20021780L (no) 1999-10-20 2002-04-16 Bicykliske aminosyrer som farmasöytiske midler
NO20043663A NO20043663L (no) 1999-10-20 2004-09-01 Bicykliske aminosyrer som farmasoytiske midler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20021780A NO20021780L (no) 1999-10-20 2002-04-16 Bicykliske aminosyrer som farmasöytiske midler

Country Status (50)

Country Link
US (2) US6689906B1 (no)
EP (2) EP1226110B1 (no)
JP (2) JP3632191B2 (no)
KR (2) KR100593349B1 (no)
CN (1) CN1165518C (no)
AP (2) AP2004003186A0 (no)
AR (2) AR026087A1 (no)
AT (2) ATE293590T1 (no)
AU (2) AU778871B2 (no)
BG (2) BG106719A (no)
BR (1) BR0014972B1 (no)
CA (1) CA2386297C (no)
CO (1) CO5280060A1 (no)
CR (1) CR6620A (no)
CU (1) CU23112A3 (no)
CZ (1) CZ295960B6 (no)
DE (2) DE60034157T2 (no)
DO (1) DOP2000000083A (no)
DZ (1) DZ3197A1 (no)
EA (1) EA005206B1 (no)
EC (1) ECSP045393A (no)
EE (1) EE200200211A (no)
ES (2) ES2237464T3 (no)
GE (1) GEP20043297B (no)
GT (2) GT200000183A (no)
HK (1) HK1049826B (no)
HN (1) HN2000000224A (no)
HR (2) HRP20020428B1 (no)
HU (1) HUP0203325A3 (no)
IL (3) IL149143A0 (no)
IS (2) IS6348A (no)
MA (1) MA26842A1 (no)
MX (1) MXPA02003229A (no)
MY (1) MY127678A (no)
NO (2) NO20021780L (no)
NZ (1) NZ517961A (no)
OA (1) OA12070A (no)
PA (1) PA8505201A1 (no)
PE (1) PE20010740A1 (no)
PL (1) PL354607A1 (no)
PT (1) PT1226110E (no)
SI (1) SI1226110T1 (no)
SK (1) SK5232002A3 (no)
SV (1) SV2001000188A (no)
TR (2) TR200201094T2 (no)
TW (2) TWI225855B (no)
UA (1) UA72931C2 (no)
WO (1) WO2001028978A1 (no)
YU (2) YU29302A (no)
ZA (1) ZA200202543B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
DK1296671T3 (da) * 2000-06-26 2008-06-16 Warner Lambert Co Gabapentinanaloger til sövnforstyrrelser
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
IL157932A0 (en) * 2001-04-19 2004-03-28 Warner Lambert Co Fused bicyclic or tricyclic amino acids
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2296956T5 (es) * 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
EP1469841A1 (en) * 2002-01-31 2004-10-27 Warner-Lambert Company Alpha 2 delta ligands to treat tinnitus
WO2003070237A1 (en) * 2002-02-22 2003-08-28 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
CN1678298A (zh) * 2002-06-27 2005-10-05 沃纳-兰伯特公司 α2δ配体如加巴喷丁或普瑞巴林用于治疗注意力缺陷的过度反应症的用途
CA2494811A1 (en) * 2002-08-15 2004-02-26 Pfizer Inc. Therapeutic use of fused bicyclic or tricyclic amino acids
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
WO2004052360A1 (en) 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
RU2353358C2 (ru) 2002-12-13 2009-04-27 Уорнер-Ламберт Компани Ллс Производные прегабалина для лечения приливов
DK1572173T3 (da) 2002-12-13 2010-06-14 Warner Lambert Co Alpha-2-delta-ligand til behandling af symptomer i den nedre urinvej
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR100828218B1 (ko) 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
KR20090092307A (ko) 2006-12-22 2009-08-31 레코르다티 아일랜드 리미티드 하요도 장애에 대한 α2δ 리간드 및 NSAIDs의 복합 치료
JP4479974B2 (ja) 2007-09-28 2010-06-09 第一三共株式会社 二環性γ−アミノ酸誘導体
JP5557292B2 (ja) 2009-03-26 2014-07-23 第一三共株式会社 二環性γ−アミノ酸誘導体の製造方法
ES2649968T3 (es) 2011-06-08 2018-01-16 Daiichi Sankyo Company, Limited Procedimiento de producción de un compuesto bicíclico vía transposición de Claisen
HUE037046T2 (hu) 2011-06-08 2018-08-28 Daiichi Sankyo Co Ltd Eljárás biciklusos vegyület elõállítására iminium són keresztül
CA2859003C (en) 2011-12-15 2016-11-01 Daiichi Sankyo Company, Limited Optical resolution method for bicyclic compound using asymmetric catalyst
IN2014DN07923A (no) 2012-04-10 2015-05-01 Daiichi Sankyo Companyltd
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ-胺基酸衍生物及其製造方法
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) * 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
CN1303059C (zh) 1997-10-27 2007-03-07 沃尼尔·朗伯公司 作为药物的环状氨基酸及其衍生物

Also Published As

Publication number Publication date
DE60019628D1 (de) 2005-05-25
IS7497A (is) 2004-10-08
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
IL149143A (en) 2007-02-11
SK5232002A3 (en) 2003-07-01
PA8505201A1 (es) 2002-08-29
CN1165518C (zh) 2004-09-08
ES2237464T3 (es) 2005-08-01
EE200200211A (et) 2003-06-16
TR200500221T2 (tr) 2005-03-21
HRP20040709A2 (en) 2004-12-31
SI1226110T1 (en) 2005-08-31
PE20010740A1 (es) 2001-07-27
CA2386297A1 (en) 2001-04-26
TW200505824A (en) 2005-02-16
CO5280060A1 (es) 2003-05-30
BG106719A (bg) 2003-02-28
OA12070A (en) 2003-11-10
BR0014972B1 (pt) 2011-09-06
IS6348A (is) 2002-04-17
CA2386297C (en) 2010-02-09
NZ517961A (en) 2002-12-20
NO20021780D0 (no) 2002-04-16
AP2004003186A0 (en) 2004-12-31
HK1049826A1 (en) 2003-05-30
IL164060A0 (en) 2005-12-18
US20040152779A1 (en) 2004-08-05
DZ3197A1 (fr) 2001-04-26
PT1226110E (pt) 2005-07-29
ECSP045393A (es) 2004-10-23
EA005206B1 (ru) 2004-12-30
AU2005201268A1 (en) 2005-04-21
YU29302A (sh) 2005-06-10
BG108860A (en) 2006-03-31
TWI225855B (en) 2005-01-01
CN1382118A (zh) 2002-11-27
US6835751B2 (en) 2004-12-28
EP1226110A1 (en) 2002-07-31
ATE293590T1 (de) 2005-05-15
EP1226110B1 (en) 2005-04-20
HRP20020428A2 (en) 2005-02-28
AP2002002517A0 (en) 2002-06-30
ES2282785T3 (es) 2007-10-16
HK1049826B (zh) 2005-02-25
HRP20020428B1 (en) 2006-02-28
MA26842A1 (fr) 2004-12-20
CU23112A3 (es) 2006-02-27
CZ20021310A3 (cs) 2003-05-14
AU1092001A (en) 2001-04-30
DE60019628T2 (de) 2006-01-19
DE60034157D1 (de) 2007-05-10
AU778871B2 (en) 2004-12-23
AR045456A2 (es) 2005-10-26
CZ295960B6 (cs) 2005-12-14
MY127678A (en) 2006-12-29
KR100593349B1 (ko) 2006-06-26
JP2003512348A (ja) 2003-04-02
HUP0203325A3 (en) 2003-12-29
UA72931C2 (uk) 2005-05-16
HUP0203325A2 (hu) 2003-02-28
MXPA02003229A (es) 2002-09-30
KR20060013701A (ko) 2006-02-13
GT200000183AA (es) 2005-06-17
EP1506955A1 (en) 2005-02-16
ZA200202543B (en) 2003-09-23
EP1506955B1 (en) 2007-03-28
ATE358116T1 (de) 2007-04-15
US6689906B1 (en) 2004-02-10
TR200201094T2 (tr) 2002-09-23
SV2001000188A (es) 2001-09-07
CR6620A (es) 2004-02-02
WO2001028978A1 (en) 2001-04-26
JP3632191B2 (ja) 2005-03-23
KR100566462B1 (ko) 2006-03-31
KR20020040900A (ko) 2002-05-30
PL354607A1 (en) 2004-01-26
AR026087A1 (es) 2002-12-26
IL149143A0 (en) 2002-11-10
BR0014972A (pt) 2002-07-16
DOP2000000083A (es) 2002-03-30
HN2000000224A (es) 2001-04-11
DE60034157T2 (de) 2007-12-13
YU73004A (sh) 2005-11-28
JP3744928B2 (ja) 2006-02-15
JP2005036009A (ja) 2005-02-10
EA200200293A1 (ru) 2002-10-31
NO20021780L (no) 2002-04-16

Similar Documents

Publication Publication Date Title
NO20021780D0 (no) Bicykliske aminosyrer som farmasöytiske midler
DK1212327T3 (da) Pyrazolopyrimidiner som terapeutiske midler
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
NO20015175L (no) Farmasöytisk sammensetning
NO20002217D0 (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
ID24654A (id) Formulasi farmasi omeprazola
NO20022887D0 (no) Lipopeptider som antibakterielle midler
DK1163239T3 (da) Modificerede aminosyreamider som CGRP-antagonister
NO20016006D0 (no) Valensplattformmolekyler som innbefatter aminooksygrupper
DK1218383T3 (da) Biocykliske imidazo-5-yl-aminoderivater
NO993901L (no) Bisykliske aminosyrer
NO20022606D0 (no) Farmasöytiske kombinasjoner
DK1227817T3 (da) Ciclesonid-holdigt vandigt farmaceutisk præparat
ID30032A (id) Formulasi farmasi
FI4488U1 (fi) Farmaseuttinen koostumus
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20016430L (no) Farmasöytisk kompleks
NO20002321D0 (no) Bifenylderivater som farmasøytiske midler
NO20004816D0 (no) Ny farmasøytisk formulering
DK1226110T3 (da) Bicycliske aminosyrer som farmaceutiske midler
SE9803952D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application